Related Experiment Videos
[Clinical effect of UFT on bladder cancer]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 1, 1982
Summary
Oral administration of UFT (a combination of futraful and uracil) showed promise in treating bladder cancer. Complete remission was observed in 5 of 14 evaluable cases, with additional benefits seen in advanced stages.
Area of Science:
- Oncology
- Pharmacology
Context:
- Recurrent and superficial bladder cancer present significant treatment challenges.
- Evaluating novel therapeutic agents is crucial for improving patient outcomes.
Purpose:
- To assess the efficacy and safety of UFT (a combination of futraful and uracil) in patients with bladder cancer.
- To determine the response rates and side effects associated with UFT therapy.
Summary:
- UFT was administered orally to 15 patients with recurrent/superficial bladder cancer at 300 or 600 mg/day for over 4 weeks.
- Complete remission was observed in 5 of 14 evaluable cases. Two advanced cases treated with UFT and irradiation showed severe tumor degeneration and complete resolution of lung metastasis.
- Side effects, primarily anorexia, were mild and did not necessitate treatment termination.
Impact:
- UFT demonstrates potential as a valuable therapeutic option for bladder cancer treatment.
- The findings support further investigation into UFT's role in managing various stages of bladder cancer.